BioPharma Resources

Drug Trial Radar · NCT07794748

A Study to Assess the Safety, Tolerability, and Immunogenicity of 3 Lots of a Multivalent Pneumococcal Conjugate Vaccine Administered to Adults

A PHASE 3, RANDOMIZED, DOUBLE-BLIND TRIAL TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF 3 LOTS OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE IN ADULTS

Last checked: Nov 19, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 4,701 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

4,701

Actual

Start

Sep 8, 2026

Primary completion

Apr 26, 2027

Study completion Apr 26, 2027

Sponsor

Lead sponsor
PfizerPfizer (PFE)
Sponsor type
Industry
First posted
Aug 31, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 49 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this study is to provide safety data and demonstrate lot consistency with the PG4 vaccine by evaluating the immunogenicity of 3 different lots of this vaccine. This study will compare a new pneumococcal vaccine with the vaccine currently in use to see if they are similarly safe. It will also compare three batches of the new vaccine to make sure they work the same way. Blood samples will be taken to measure how the body responds to the vaccines. The study will be conducted in the United States. Participants will be assigned to 1 of 4 groups. Group 1: PG4 vaccine lot 1; Group 2: PG4 vaccine lot 2; Group 3: PG4 vaccine lot 3; Group 4: 20vPnC. Within each group, participants will be assigned by chance in a 2:2:2:1 ratio to receive 1 vaccine injection (shot) with either PG4 (new vaccine) lot 1, PG4 lot 2, PG4 Lot 3 or 20vPnC, given in the arm. This means that for every 7 participants, about 2 will receive either PG4 lot 1, lot 2 or lot 3 and about 1 will receive 20vPnC. Each participant will take part in the study for approximately 6 months.

Conditions

  • Pneumococcal Disease

Interventions

  • PG4 Multivalent VaccineBiological

    Multivalent Pneumococcal Vaccine

  • PG4 Multivalent VaccineBiological

    Multivalent Pneumococcal Vaccine

  • PG4 Multivalent VaccineBiological

    Multivalent Pneumococcal Vaccine

  • 20 Valent Pneumococcal Conjugate Vaccine (20vPnC)Biological

    20 Valent Pneumococcal Conjugate Vaccine

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants with Prespecified Local Reactions Within 7 Days After VaccinationTime frame: Within 7 days after Vaccination
  2. Percentage of Participants reporting Prespecified Systemic Events Within 7 Days after VaccinationTime frame: Within 7 days after Vaccination
  3. Percentage of Participants with Adverse Events (AEs)Time frame: From Vaccination to 1 month after Vaccination
  4. Percentage of Participants with Serious Adverse Events (SAEs)Time frame: From Vaccination to 6 months after Vaccination
  5. OPA geometric mean ratios (GMR) between each pair of PG4 vaccine lotsTime frame: 1 month after Vaccination

Locations

37 sites in 1 country. Site status is shown where the registry gives one.

  • Achieve Clinical Research, LLC d/b/a Accel Research Sites - Birmingham Clinical Research Unit

    Birmingham, Alabama

  • Orange County Research Center

    Lake Forest, California

  • Diablo Clinical Research, LLC dba Flourish Research

    Walnut Creek, California

  • Clinical Research Consulting

    Milford, Connecticut

  • Suncoast Research Associates

    Doral, Florida

  • Research Centers of America

    Hollywood, Florida

  • East Coast Institute for Research, LLC

    Jacksonville, Florida

  • Entrust Clinical Research

    Miami, Florida

  • Palm Springs Community Health Center

    Miami Lakes, Florida

  • Indago Research and Health Center, Inc.

    Miami Lakes, Florida

  • Innovation Medical Research, LLC

    Palmetto Bay, Florida

  • Palm Beach Research Center

    West Palm Beach, Florida

  • Javara Inc.

    Fayetteville, Georgia

  • Clinical Research Atlanta

    Stockbridge, Georgia

  • East-West Medical Research Institute

    Honolulu, Hawaii

  • DM Clinical Research

    Melrose Park, Illinois

  • Velocity Clinical Research, Sioux City

    Sioux City, Iowa

  • Henry Ford St. John Hospital - Thomas Mackey Center for Infectious Disease Research

    Grosse Pointe Woods, Michigan

  • Clinical Research Professionals

    Chesterfield, Missouri

  • Bio-Kinetic Clinical Applications, LLC dba QPS-MO

    Springfield, Missouri

  • Bio-Kinetic Clinical Applications, LLC dba QPS-MO-Screening and Recruitment Center

    Springfield, Missouri

  • Sundance Clinical Research, LLC

    St Louis, Missouri

  • Velocity Clinical Research, Grand Island

    Grand Island, Nebraska

  • South Jersey Infectious Disease

    Somers Point, New Jersey

  • Accellacare - Wilmington

    Wilmington, North Carolina

  • Cincinnati Children's Hospital Medical Center Investigational Drug Services

    Cincinnati, Ohio

  • Cincinnati Children's Hospital Medical Center Vaccine Research Center

    Cincinnati, Ohio

  • CTI Clinical Research Center

    Cincinnati, Ohio

  • DM Clinical Research

    Philadelphia, Pennsylvania

  • Clinical Trials of South Carolina

    Moncks Corner, South Carolina

  • TMA Headlands LLC (d/b/a Trial Management Associates)

    Myrtle Beach, South Carolina

  • Coastal Carolina Research Center, LLC

    North Charleston, South Carolina

  • SMS Clinical Research LLC

    Mesquite, Texas

  • DM Clinical Research - Sugar Land

    Sugar Land, Texas

  • DM Clinical Research

    Tomball, Texas

  • J. Lewis Research, Inc. / Foothill Family Clinic

    Salt Lake City, Utah

  • J. Lewis Research, Inc. / Foothill Family Clinic South

    Salt Lake City, Utah

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.